Your browser is no longer supported. Please, upgrade your browser.
Settings
VRTX Vertex Pharmaceuticals Incorporated daily Stock Chart
VRTX [NASD]
Vertex Pharmaceuticals Incorporated
IndexS&P 500 P/E213.56 EPS (ttm)0.86 Insider Own0.20% Shs Outstand247.08M Perf Week4.27%
Market Cap45.11B Forward P/E39.93 EPS next Y4.57 Insider Trans-56.36% Shs Float247.08M Perf Month17.78%
Income225.70M PEG3.21 EPS next Q0.74 Inst Own97.20% Short Float1.11% Perf Quarter10.67%
Sales2.41B P/S18.68 EPS this Y327.00% Inst Trans-0.10% Short Ratio1.67 Perf Half Y17.26%
Book/sh9.48 P/B19.26 EPS next Y42.86% ROA- Target Price191.45 Perf Year41.31%
Cash/sh10.03 P/C18.21 EPS next 5Y66.50% ROE- 52W Range127.67 - 183.39 Perf YTD21.84%
Dividend- P/FCF- EPS past 5Y47.60% ROI8.80% 52W High-1.24% Beta1.50
Dividend %- Quick Ratio3.50 Sales past 5Y10.30% Gross Margin87.70% 52W Low41.87% ATR4.31
Employees2300 Current Ratio3.70 Sales Q/Q-10.30% Oper. Margin- RSI (14)71.11 Volatility1.82% 2.55%
OptionableYes Debt/Eq0.25 EPS Q/Q-18.40% Profit Margin- Rel Volume0.45 Prev Close182.59
ShortableYes LT Debt/Eq0.24 EarningsJul 25 AMC Payout- Avg Volume1.65M Price181.12
Recom1.80 SMA208.90% SMA5014.41% SMA20015.76% Volume528,105 Change-0.81%
Mar-05-18Reiterated Maxim Group Buy $195 → $200
Feb-13-18Reiterated JMP Securities Mkt Outperform $200 → $211
Feb-01-18Reiterated Barclays Overweight $180 → $200
Jan-05-18Upgrade BofA/Merrill Neutral → Buy
Oct-18-17Reiterated RBC Capital Mkts Outperform $175 → $181
Sep-29-17Initiated BTIG Research Buy $200
Sep-15-17Initiated RBC Capital Mkts Outperform $175
Jul-19-17Upgrade Raymond James Mkt Perform → Outperform
Jul-19-17Upgrade Janney Neutral → Buy
Jul-19-17Upgrade Barclays Equal Weight → Overweight $115 → $180
Jul-19-17Reiterated Stifel Buy $154 → $182
Jul-18-17Reiterated Stifel Buy $130 → $154
Jul-11-17Initiated Jefferies Buy
Jun-23-17Upgrade Needham Hold → Buy $155
Jun-02-17Upgrade Oppenheimer Perform → Outperform
Mar-31-17Upgrade Maxim Group Hold → Buy $143
Mar-17-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Mar-09-17Initiated UBS Buy $106
Mar-01-17Initiated Citigroup Buy $105
Jan-26-17Reiterated Stifel Buy $108 → $100
Jul-16-18 01:05PM  CRISPR Therapeutics Stock History: The Rise of the World's Biggest Gene-Editing Biotech Motley Fool
Jul-12-18 04:01PM  Vertex to Announce Second Quarter 2018 Financial Results on July 25 Business Wire
Jul-08-18 03:15PM  Why bluebird bio's Shares Have Tumbled 11.9% in 2018 So Far Motley Fool
Jul-05-18 02:40PM  Drug pricing debate could heat up in July CNBC Videos
Jul-02-18 10:06AM  Company News For Jul 2, 2018 Zacks
09:02AM  Vertex's Shares Rally as a Rival's CF Candidate Disappoints Zacks
08:10AM  Today's Research Reports on Stocks to Watch: Acceleron Pharma and Vertex Pharmaceuticals ACCESSWIRE
Jun-29-18 06:07PM  After the Bell: For the Dow, a Good Quarter, but a Bad Year Barrons.com +15.16%
04:52PM  Vertex Pops As Rival Disappoints In Cystic Fibrosis And AbbVie Opts Out Investor's Business Daily
03:27PM  Vertex Pharma Jumps 14% After Rival Releases Poor Cystic Fibrosis Drug Results TheStreet.com
12:19PM  Why Vertex Pharmaceuticals Incorporated Stock Surged 14% Today Motley Fool
10:45AM  Bad News Delivers a Decisive Blow to Galapagos N.V. Motley Fool
09:41AM  Stocks Jump As Nike, Wells Fargo, Vertex Lead Early Rally Investor's Business Daily
08:11AM  Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos Benzinga
04:53AM  Premarket: Futures Rise As Banks Rally On Stress Test; Nike Spikes Investor's Business Daily
Jun-28-18 11:19AM  Health Canada Approves PrSYMDEKO (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene Business Wire
Jun-26-18 11:26AM  The 10 Fastest-Growing Stocks to Invest In Right Now InvestorPlace
06:30AM  This Biotech Has the Most Valuable Pipeline Asset in the World -- Is the Stock a Buy? Motley Fool
Jun-25-18 09:31AM  You Should Consider Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Because Of These Reasons Simply Wall St.
Jun-21-18 03:25PM  Vertexs Paul Negulescu Awarded the Warren Alpert Foundation Prize for Pioneering Discoveries in Cystic Fibrosis Business Wire
11:49AM  3 Big Biotechs That Can Beat the Market Investopedia
Jun-20-18 11:30AM  2 High-Flying Biotech Stocks With Even More Room to Grow Motley Fool
Jun-18-18 01:00PM  Vertex Opens Expanded Research Site in San Diego Business Wire
07:00AM  Vertex Announces Long-Term Access Agreement in Sweden for Cystic Fibrosis Medicine ORKAMBI® (lumacaftor/ivacaftor) Business Wire
Jun-15-18 10:37AM  Big Biotech Set for Earnings Blowout? Barrons.com
Jun-14-18 09:30AM  The Vertex Foundation and Employees Donate $1 Million Through Matching Gift Program Business Wire
Jun-12-18 05:00AM  The Quant King, the Drug Hunter, and the Quest to Unlock New Cures Bloomberg
Jun-11-18 10:31AM  2 Cheap Growth Stocks to Buy Right Now Motley Fool
Jun-08-18 09:18AM  Now's the Time to Buy These 3 Stocks Motley Fool
Jun-07-18 05:20PM  Vertex Gets Some Breathing Room As Rival Disappoints In Cystic Fibrosis Investor's Business Daily
04:30AM  Vertex Data Presented at European Cystic Fibrosis Society (ECFS) Conference Demonstrate Early and Long-Term Disease-Modifying Potential of Treating the Underlying Cause of CF Business Wire
Jun-06-18 04:01PM  Vertex to Present at the Goldman Sachs Healthcare Conference on June 13 Business Wire
08:31AM  Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO Zacks
Jun-05-18 04:10PM  Interested In Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)? Heres What Its Recent Performance Looks Like Simply Wall St.
07:20AM  Free Technical Research on Versartis and Three More Biotech Equities ACCESSWIRE
06:33AM  Buy These 2 Biotech Stocks on the Dip After an FDA Delay Motley Fool
12:21AM  After Soaring to New Highs, Crispr Therapeutics AG Stock Ripe for a Fall InvestorPlace
Jun-01-18 08:41AM  Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex Zacks
May-31-18 03:10PM  Should You Buy the Dip in CRISPR Therapeutics? Zacks
11:45AM  3 Possible Outcomes From The Clinical Hold On Crispr Therapeutics's Sickle Cell Candidate Benzinga
11:05AM  Peaking late: How Vertex became biotech's model citizen American City Business Journals
10:09AM  Vertex/CRISPR's Sickle Disease Candidate Put on Hold by FDA Zacks
08:31AM  4 Reasons Not to Worry About Crispr Therapeutics AG's Latest Setback Motley Fool
07:55AM  Is Crispr Therapeutics Stock a Bad News Buy? Motley Fool
07:02AM  Dow Jones Futures: Hot Biotech Dives On FDA; 3 Breakout Bids With Flaws Investor's Business Daily
May-30-18 08:19PM  CRISPR, Vertex say FDA puts brakes on upcoming gene editing trial American City Business Journals
05:02PM  Crispr, Vertex shares fall after FDA halts sickle-cell disease trial MarketWatch
04:51PM  FDA places clinical hold on drug CNBC Videos
04:46PM  Gene-Therapy Company Crispr Drops as FDA Puts Trial on Hold Bloomberg
04:30PM  CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease GlobeNewswire
May-28-18 02:50AM  Vertex Pharmaceuticals (VRTX) Down 1.2% Since Earnings Report: Can It Rebound? Zacks
May-25-18 08:10PM  3 Stocks That Could Put Alibaba's Returns to Shame Motley Fool
May-16-18 10:09AM  The Zacks Analyst Blog Highlights: General Dynamics, Enbridge, CSX, Humana and Vertex Zacks
07:00AM  CRISPR Stocks Deserve a Second Look. Here's Why. Investopedia
May-10-18 08:10AM  Factors of Influence in 2018, Key Indicators and Opportunity within American Homes 4 Rent, Discovery Communications, Vertex Pharmaceuticals, The New York Times, Palatin Technologies, and E*TRADE Financial New Research Emphasizes Economic Growth GlobeNewswire
May-09-18 06:00AM  3 Top Biotech Stocks to Buy in May Motley Fool
May-08-18 12:18PM  7 Fast-Growing Stocks to Buy Today InvestorPlace
06:32AM  Here's My Top Stock to Buy in May Motley Fool
May-07-18 02:10PM  MARKETS: Here's why stellar earnings aren't boosting stocks higher Yahoo Finance Video
May-02-18 09:23AM  Biotech Stock Roundup: ALXN, VRTX Post Solid Results, GILD Disappoints in Q1 Zacks
May-01-18 08:30AM  Vertex Awards $400,000 in Scholarships to People Living with Cystic Fibrosis and Their Immediate Family Members Business Wire
07:40AM  Blog Exposure - EMA Scientific Committee Recommended Granting Marketing Authorization to Gilead's Biktarvy(R) for HIV-1 Treatment ACCESSWIRE
07:00AM  Medicaid Is Right to Demand Lower Drug Prices Bloomberg
Apr-30-18 03:48PM  Vertex Pharmaceuticals Takes a Detour Around the FDA's Roadblock Motley Fool
02:51PM  MARKETS: Oil markets react to Iran latest, Apple stocks up ahead of earnings report, Walmart helps retails sector Yahoo Finance Video
09:20AM  Google's Alphabet Median Pay Close To $200K Investopedia
Apr-29-18 11:45PM  Edited Transcript of VRTX earnings conference call or presentation 26-Apr-18 8:30pm GMT Thomson Reuters StreetEvents
11:35AM  Stocks This Week: Buy Visa, Vertex And Apple Forbes
06:32AM  5 Things You'll Want to Know From Vertex Pharmaceuticals' Q1 Conference Call Motley Fool
Apr-27-18 04:01PM  Vertex Slips As FDA Delays Cystic Fibrosis Drug But There's A Silver Lining Investor's Business Daily
10:54AM  Vertex (VRTX) Q1 Earnings Beat on Strong CF Products Sales Zacks
Apr-26-18 06:33PM  Vertex Pharma profit tops estimates on strong launch of new CF drug Reuters
05:30PM  Vertex Pharma Tops Quarterly Views On Strong Cystic Fibrosis Drug Sales Investor's Business Daily
04:56PM  Vertex: 1Q Earnings Snapshot Associated Press
04:31PM  Vertex Pharma's quarterly profit falls 15.1 percent Reuters
04:05PM  Vertex Reports First-Quarter 2018 Financial Results Business Wire
04:01PM  Vertex Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis Business Wire
Apr-25-18 10:56AM  Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX Zacks
10:55AM  At Mass. forum, health care heavyweights say AI is new frontier of medicine American City Business Journals
Apr-24-18 09:11AM  Is a Beat in Store for Vertex (VRTX) This Earnings Season? Zacks
08:52AM  Why Earnings Season Could Be Great for Vertex Pharmaceuticals (VRTX) Zacks
Apr-18-18 06:10AM  3 Growth Stocks That Could Put Facebook's Returns to Shame Motley Fool
Apr-17-18 04:01PM  Vertex to Announce First Quarter 2018 Financial Results on April 26 Business Wire
Apr-16-18 08:17AM  The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte Zacks
Apr-13-18 06:31PM  3 Top Healthcare Stocks to Buy in April Motley Fool
Apr-12-18 07:19AM  Is PowerShares Dynamic Biotechnology & Genome Portfolio (PBE) a Hot ETF Right Now? Zacks
Apr-11-18 12:22PM  Vertex Is Worth More Than You Think Barrons.com
Apr-06-18 02:23PM  10 Healthcare Stocks to Stave Off the Market Flu InvestorPlace
Mar-29-18 02:18PM  Vertex Appoints Kimberly A. White as Senior Vice President and Chief Communications Officer Business Wire
Mar-27-18 06:38PM  Is Vertex Pharmaceuticals Incorporateds (NASDAQ:VRTX) PE Ratio A Signal To Sell For Investors? Simply Wall St.
06:31AM  Investing in These Stocks Now Could Make You a Millionaire Retiree Motley Fool
Mar-21-18 01:06PM  NYSE trader: Facebook is too big to fail, so I'm sticking with tech stocks Yahoo Finance Video
Mar-20-18 08:00AM  12 Growth Stocks That Will Win Long Term: Goldman Investopedia
Mar-19-18 04:55PM  3 Highest-Growth Stocks in the Market Today Motley Fool
Mar-16-18 01:38PM  Trying the Long Side of Vertex's Stock Again TheStreet.com
12:23PM  Why A Biopharma Buying Spree May Target AstraZeneca, Bristol Investor's Business Daily
11:52AM  117 Top-Rated Mutual Funds Own Shares In This Potential Breakout Stock Investor's Business Daily
11:10AM  Trying the Long Side of Vertex Again TheStreet.com
Mar-15-18 05:09PM  Why CRISPR Therapeutics Slipped 10% on Thursday Motley Fool
09:19AM  7 Things Vertex Pharmaceuticals' CEO Just Said That Will Probably Make You Want to Buy the Stock Motley Fool
Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor. The company also develops VX-659 and VX-445, which are CFTR corrector compounds in Phase II clinical trial; VX-150 that is in Phase II clinical trial to treat pain; VX-128, which is in Phase I clinical trial for the treatment of pain; CTX001, an investigational gene editing treatment that is in Phase I/II trial for the treatment of beta-thalassemia and sickle cell disease; pimodivir (JNJ-63623872), which is in a Phase III clinical development program to treat influenza; and VX-210 to treat acute spinal cord injury. It sells its products primarily to specialty pharmacy providers in North America, as well as government-owned and supported customers internationally. The company has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Parion Sciences, Inc.; Merck KGaA; Janssen Pharmaceuticals, Inc; and Q-State Biosciences, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 16Option Exercise96.872,125205,84948,877Jul 17 06:23 PM
Sachdev AmitEVP, CROJul 16Option Exercise96.871,719166,52048,381Jul 17 06:30 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 16Sale179.852,125382,18146,752Jul 17 06:23 PM
Sachdev AmitEVP, CROJul 16Sale180.361,719310,04246,662Jul 17 06:30 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 13Option Exercise131.896,375840,79953,127Jul 17 06:23 PM
Sachdev AmitEVP, CROJul 13Option Exercise96.8712,0311,165,44358,693Jul 17 06:30 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 13Sale179.006,3751,141,12546,752Jul 17 06:23 PM
Sachdev AmitEVP, CROJul 13Sale180.0012,0312,165,58046,662Jul 17 06:30 PM
Silva Paul MSVP & Corp ControllerJul 12Option Exercise90.2986077,64916,947Jul 16 04:19 PM
Parini MichaelEVP, CL&AOJul 12Option Exercise90.292,125191,86641,734Jul 16 04:37 PM
Silva Paul MSVP & Corp ControllerJul 12Sale175.02860150,51716,087Jul 16 04:19 PM
Parini MichaelEVP, CL&AOJul 12Sale175.022,125371,91839,609Jul 16 04:37 PM
Parini MichaelEVP, CL&AOJul 05Option Exercise122.454,250520,41343,859Jul 09 06:14 PM
Parini MichaelEVP, CL&AOJul 05Sale168.384,250715,61539,609Jul 09 06:14 PM
Sachdev AmitEVP, CROJun 29Option Exercise88.904,096364,14850,758Jul 03 04:12 PM
Silva Paul MSVP & Corp ControllerJun 29Option Exercise91.502,957270,56917,376Jul 03 04:16 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 29Option Exercise89.153,708330,57850,460Jul 03 04:20 PM
SMITH IAN FEVP, COOJun 29Option Exercise131.8923,3753,082,92970,074Jul 03 04:25 PM
ALTSHULER DAVIDEVP, Global Research and CSOJun 29Option Exercise87.1313,4451,171,39783,444Jul 03 04:29 PM
Sachdev AmitEVP, CROJun 29Sale167.634,096686,61546,662Jul 03 04:12 PM
Silva Paul MSVP & Corp ControllerJun 29Sale166.522,957492,38516,087Jul 03 04:16 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 29Sale169.003,708626,65246,752Jul 03 04:20 PM
SMITH IAN FEVP, COOJun 29Sale166.3023,3753,887,17346,699Jul 03 04:25 PM
ALTSHULER DAVIDEVP, Global Research and CSOJun 29Sale164.9844,3317,313,59639,113Jul 03 04:29 PM
LEIDEN JEFFREY MCEO & PresidentJun 22Option Exercise83.36106,5008,877,840297,260Jun 26 05:18 PM
SMITH IAN FEVP, COOJun 22Option Exercise109.144,250463,84550,949Jun 26 05:18 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 22Option Exercise109.144,250463,84551,002Jun 26 05:20 PM
LEIDEN JEFFREY MCEO & PresidentJun 22Sale160.00140,21122,433,760157,049Jun 26 05:18 PM
SMITH IAN FEVP, COOJun 22Sale160.004,250680,00046,699Jun 26 05:18 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 22Sale159.004,250675,75046,752Jun 26 05:20 PM
Bhatia Sangeeta N.DirectorJun 04Sale152.05875133,0444,879Jun 05 05:39 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 15Sale155.789815,26669,999May 16 04:48 PM
Sachdev AmitEVP, CROMay 15Sale155.788312,93046,662May 16 05:06 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 15Sale155.7813821,49846,752May 16 05:11 PM
SMITH IAN FEVP, COOMay 15Sale155.7821733,80446,699May 16 05:21 PM
Parini MichaelEVP, CL&AOMay 15Sale155.788513,24139,609May 16 05:24 PM
Silva Paul MSVP & Corp ControllerMay 15Sale155.7820131,31216,087May 16 05:27 PM
Parini MichaelEVP, CL&AOMay 03Option Exercise86.522,330201,59241,939May 04 04:23 PM
Parini MichaelEVP, CL&AOMay 03Sale149.502,330348,33539,609May 04 04:23 PM
SMITH IAN FEVP, COOApr 26Option Exercise108.6553,1255,771,98999,824Apr 27 04:37 PM
Parini MichaelEVP, CL&AOApr 26Option Exercise122.4538,2504,683,71377,859Apr 27 04:38 PM
SMITH IAN FEVP, COOApr 26Sale160.1253,1258,506,37546,699Apr 27 04:37 PM
Parini MichaelEVP, CL&AOApr 26Sale159.5638,2506,103,17039,609Apr 27 04:38 PM
SMITH IAN FEVP, COOApr 25Option Exercise84.4514,1721,196,78678,667Apr 27 04:37 PM
Parini MichaelEVP, CL&AOApr 25Option Exercise90.292,125191,86642,123Apr 27 04:38 PM
SMITH IAN FEVP, COOApr 25Sale155.3331,9684,965,52646,699Apr 27 04:37 PM
Parini MichaelEVP, CL&AOApr 25Sale155.222,514390,23339,609Apr 27 04:38 PM
Silva Paul MSVP & Corp ControllerApr 18Option Exercise90.2985977,55916,946Apr 19 05:37 PM
Silva Paul MSVP & Corp ControllerApr 18Sale166.05859142,63716,087Apr 19 05:37 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerApr 16Option Exercise96.872,125205,84948,877Apr 18 02:50 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerApr 16Sale163.012,125346,39646,752Apr 18 02:50 PM
Silva Paul MSVP & Corp ControllerApr 02Sale161.213,438554,24916,087Apr 04 05:07 PM
Sachdev AmitEVP, CROMar 09Option Exercise96.8713,7501,331,96360,412Mar 12 05:36 PM
Sachdev AmitEVP, CROMar 09Sale175.0013,7502,406,25046,662Mar 12 05:36 PM
MCGLYNN MARGARET GDirectorMar 02Option Exercise81.5410,000815,40016,312Mar 05 06:13 PM
MCGLYNN MARGARET GDirectorMar 02Sale170.0010,0001,700,0006,312Mar 05 06:13 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 26Option Exercise86.521,554134,45253,211Feb 28 09:22 AM
Sachdev AmitEVP, CROFeb 26Option Exercise91.052,155196,21348,817Feb 28 09:30 AM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 26Sale169.006,4591,091,57146,752Feb 28 09:22 AM
Sachdev AmitEVP, CROFeb 26Sale170.002,155366,35046,662Feb 28 09:30 AM
Silva Paul MSVP & Corp ControllerFeb 20Sale158.493,437544,73019,525Feb 21 06:16 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 13Sale151.834,044614,00151,657Feb 15 04:23 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 12Sale150.826,403965,67169,999Feb 14 05:53 PM
LEIDEN JEFFREY MCEO & PresidentFeb 12Sale150.8323,9053,605,547190,658Feb 14 06:06 PM
Chodakewitz JeffreyEVP GMDA, CMOFeb 12Sale150.825,122772,49369,663Feb 14 06:15 PM
Sachdev AmitEVP, CROFeb 12Sale150.8417,7962,684,41146,662Feb 14 06:23 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 12Sale152.826,8241,042,83355,701Feb 14 06:16 PM
Parini MichaelEVP, CL&AOFeb 05Option Exercise86.522,330201,59227,823Feb 07 05:56 PM
Chodakewitz JeffreyEVP GMDA, CMOFeb 05Option Exercise109.143,594392,24956,118Feb 07 06:16 PM
Sachdev AmitEVP, CROFeb 05Option Exercise81.274,520367,32743,683Feb 07 06:26 PM
Silva Paul MSVP & Corp ControllerFeb 05Option Exercise80.862,098169,64718,732Feb 07 05:37 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 05Option Exercise93.238,500792,41350,452Feb 07 05:46 PM
Parini MichaelEVP, CL&AOFeb 05Sale163.082,330379,97625,493Feb 07 05:56 PM
Chodakewitz JeffreyEVP GMDA, CMOFeb 05Sale161.463,594580,30452,524Feb 07 06:16 PM
Sachdev AmitEVP, CROFeb 05Sale163.014,520736,80039,163Feb 07 06:26 PM
Silva Paul MSVP & Corp ControllerFeb 05Sale163.082,098342,14216,634Feb 07 05:37 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 05Sale163.088,5001,386,18041,952Feb 07 05:46 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 02Option Exercise91.052,156196,30444,108Feb 05 05:11 PM
Silva Paul MSVP & Corp ControllerFeb 02Option Exercise91.051,289117,36317,923Feb 05 05:39 PM
Chodakewitz JeffreyEVP GMDA, CMOFeb 02Option Exercise91.051,796163,52654,320Feb 05 05:43 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 02Option Exercise91.051,796163,52651,557Feb 05 05:47 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 02Sale169.422,156365,27041,952Feb 05 05:11 PM
Silva Paul MSVP & Corp ControllerFeb 02Sale169.421,289218,38216,634Feb 05 05:39 PM
Chodakewitz JeffreyEVP GMDA, CMOFeb 02Sale166.111,796298,32952,524Feb 05 05:43 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 02Sale166.111,796298,33049,761Feb 05 05:47 PM
Silva Paul MSVP & Corp ControllerFeb 01Option Exercise96.878,594832,50125,228Feb 05 05:39 PM
Parini MichaelEVP, CL&AOFeb 01Sale174.113,450600,68025,493Feb 05 05:35 PM
Silva Paul MSVP & Corp ControllerFeb 01Sale174.118,5941,496,30116,634Feb 05 05:39 PM
Chodakewitz JeffreyEVP GMDA, CMOFeb 01Sale167.441,900318,13652,524Feb 05 05:43 PM
Sachdev AmitEVP, CROJan 29Option Exercise91.0515,0851,373,48954,248Jan 30 05:10 PM
Sachdev AmitEVP, CROJan 29Sale170.0015,0852,564,45039,163Jan 30 05:10 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJan 24Option Exercise88.708,969795,52250,921Jan 26 04:46 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJan 24Sale169.008,9691,515,76141,952Jan 26 04:46 PM
Sachdev AmitEVP, CROJan 23Option Exercise86.525,824503,89244,987Jan 25 06:33 PM
Silva Paul MSVP & Corp ControllerJan 23Option Exercise90.623,008272,57219,642Jan 24 05:33 PM
MCGLYNN MARGARET GDirectorJan 23Option Exercise59.5510,000595,50016,217Jan 24 05:35 PM
Sachdev AmitEVP, CROJan 23Sale165.005,824960,96039,163Jan 25 06:33 PM
Silva Paul MSVP & Corp ControllerJan 23Sale166.053,008499,47816,634Jan 24 05:33 PM
MCGLYNN MARGARET GDirectorJan 23Sale165.0010,0001,650,0006,217Jan 24 05:35 PM
Sachdev AmitEVP, CROJan 22Option Exercise83.3613,7501,146,20052,913Jan 23 04:56 PM